MedTrace Logo

GR Defect in Sputum Cells in COPD

NCT00159276 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-04-04

No results posted yet for this study

Summary

To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

PROCEDURE

Induced Sputum

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Sergei A Kharitonov, MD PhD · Imperial College London

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00159276 on ClinicalTrials.gov